C
Celadon Pharmaceuticals PLC
LSE:CEL
Celadon Pharmaceuticals PLC
LSE:CEL
Price:
13.4
GBX
Market Closed
Market Cap:
£9.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
UK |
|
Churchill Capital Corp VII
NASDAQ:CVII
|
US |
|
B
|
Benares Hotels Ltd
BSE:509438
|
IN |
|
G
|
Gap Inc
SWB:GAP
|
US |
|
T
|
Third Harmonic Bio Inc
NASDAQ:THRD
|
US |
|
ARMOUR Residential REIT Inc
F:2AR1
|
US |
Cash Flow Statement
Cash Flow Statement
Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals PLC
Currency: GBP
| Feb-2021 | Aug-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||
| Net Income |
(0)
|
(0)
|
(5)
|
(14)
|
(17)
|
(8)
|
(7)
|
(5)
|
(366)
|
(502)
|
(708)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
24
|
1
|
20
|
1
|
19
|
24
|
28
|
|
| Change in Deffered Taxes |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
6
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Non-Cash Items |
0
|
0
|
1
|
10
|
110
|
2
|
67
|
(0)
|
48
|
70
|
177
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Change in Working Capital |
0
|
0
|
0
|
(2)
|
20
|
(0)
|
(194)
|
(1)
|
156
|
211
|
195
|
|
| Cash from Operating Activities |
(0)
N/A
|
(0)
-35%
|
(3)
-780%
|
(6)
-87%
|
(496)
-8 336%
|
(6)
+99%
|
(260)
-4 184%
|
(6)
+98%
|
(143)
-2 472%
|
(197)
-38%
|
(308)
-57%
|
|
| Investing Cash Flow | ||||||||||||
| Capital Expenditures |
0
|
0
|
(1)
|
(1)
|
(37)
|
(1)
|
(12)
|
(0)
|
(2)
|
(2)
|
(27)
|
|
| Other Items |
0
|
0
|
(1)
|
3
|
(221)
|
(0)
|
387
|
0
|
(279)
|
(298)
|
(203)
|
|
| Cash from Investing Activities |
0
N/A
|
0
N/A
|
(1)
N/A
|
2
N/A
|
(259)
N/A
|
(1)
+100%
|
375
N/A
|
(0)
N/A
|
(280)
-176 303%
|
(300)
-7%
|
(230)
+23%
|
|
| Financing Cash Flow | ||||||||||||
| Net Issuance of Common Stock |
2
|
2
|
3
|
9
|
39
|
0
|
63
|
5
|
332
|
343
|
343
|
|
| Net Issuance of Debt |
0
|
0
|
5
|
(2)
|
(2)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Other |
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
2
N/A
|
2
N/A
|
8
+372%
|
8
-4%
|
39
+406%
|
(0)
N/A
|
63
N/A
|
4
-93%
|
332
+7 966%
|
343
+3%
|
343
+0%
|
|
| Change in Cash | ||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Net Change in Cash |
1
N/A
|
1
-7%
|
4
+168%
|
4
+16%
|
(716)
N/A
|
(7)
+99%
|
177
N/A
|
(2)
N/A
|
(91)
-5 624%
|
(154)
-69%
|
(195)
-26%
|
|
| Free Cash Flow | ||||||||||||
| Free Cash Flow |
(0)
N/A
|
(0)
-35%
|
(4)
-931%
|
(7)
-91%
|
(533)
-7 481%
|
(7)
+99%
|
(272)
-3 673%
|
(6)
+98%
|
(145)
-2 419%
|
(199)
-37%
|
(335)
-69%
|
|
Switch to:
Switch to:
See Also
Discover More
